Total | Untreated | BCS | Mx with IBR | Mx without IBR | Chemotherapy | Hormonal treatment | Other | |
---|---|---|---|---|---|---|---|---|
DCIS | ||||||||
2018/2019, wk 2–17 | 42.8 | 3.9 (9.1) | 27.9 (65.2) | 5.0 (11.8) | 5.4 (12.6) | 0.2 (0.4) | 0.4 (0.9) | 0.0 (0.2) |
2020, wk 2–8 | 49.7 | 8.1 (16.4) ↑ | 29.7 (59.8) | 5.1 (10.3) | 6.4 (12.9) | 0.1 (0.3) | 0.1 (0.3) | 0.0 (0.0) |
2020, wk 9–11 | 41.3 | 7.3 (17.7) ↑ | 22.7 (54.8) | 3.7 (8.9) | 7.0 (16.9) | 0.0 (0.0) | 0.7 (1.6) | 0.0 (0.0) |
2020, wk 12–13 | 32.0 | 3.5 (10.9) | 19.5 (60.9)a | 2.0 (6.3) | 5.5 (17.2) | 0.0 (0.0) | 1.5 (4.7)b | 0.0 (0.0) |
2020, wk 14–17 | 9.8 | 1.0 (10.3) | 4.5 (46.2) | 2.0 (20.5) | 1.8 (17.9) | 0.3 (2.6) | 0.3 (2.6) | 0.0 (0.0) |
Stage I | ||||||||
2018/2019, wk 2–17 | 147.0 | 2.7 (1.8) | 103.0 (70.1) | 10.1 (6.9) | 16.8 (11.4) | 7.1 (4.8) | 7.3 (4.9) | 0.2 (0.1) |
2020, wk 2–8 | 153.1 | 2.6 (1.7) | 104.6 (68.3) | 8.9 (5.8)c | 18.0 (11.8) | 9.1 (6.0) | 9.9 (6.4) | 0.1 (0.1) |
2020, wk 9–11 | 138.7 | 1.7 (1.2) | 95.0 (68.5) | 10.0 (7.2) | 17.7 (12.7) | 2.3 (1.7) ↓ | 12.0 (8.7)d | 0.0 (0.0) |
2020, wk 12–13 | 83.5 | 1.0 (1.2) | 55.5 (66.5) | 3.5 (4.2) | 9.5 (11.4) | 3.0 (3.6) | 11.0 (13.2)e | 0.0 (0.0) |
2020, wk 14–17 | 52.5 | 0.8 (1.4) | 29.0 (55.2) ↓ | 4.8 (9.0) | 7.5 (14.3) | 5.0 (9.5) ↑ | 5.5 (10.5) ↑ | 0.0 (0.0) |
Stage II | ||||||||
2018/2019, wk 2–17 | 119.1 | 2.6 (2.2) | 36.3 (30.5) | 5.3 (4.5) | 20.9 (17.6) | 37.5 (31.5) | 16.0 (13.4) | 0.4 (0.4) |
2020, wk 2–8 | 127.1 | 2.9 (2.2) | 35.9 (28.2) | 5.9 (4.6) | 21.7 (17.1) | 38.7 (30.4) | 21.9 (17.2)f | 0.3 (0.2) |
2020, wk 9–11 | 105.3 | 3.3 (3.2) | 32.0 (30.4) | 3.3 (3.2) | 20.0 (19.0) | 22.7 (21.5) ↓ | 24.0 (22.8)d | 0.0 (0.0) |
2020, wk 12–13 | 71.0 | 1.0 (1.4) | 22.5 (31.7) | 1.5 (2.1) | 10.5 (14.8) | 20.0 (28.2) | 15.5 (21.8)g | 0.0 (0.0) |
2020, wk 14–17 | 66.0 | 1.0 (1.5) | 17.3 (26.1) | 2.0 (3.0) | 12.3 (18.6) | 22.5 (34.1) | 11.0 (16.7) | 0.0 (0.0) |
Stage III | ||||||||
2018/2019, wk 2–17 | 32.7 | 0.8 (2.6) | 2.0 (6.2) | 0.6 (1.8) | 5.9 (18.1) | 17.5 (53.6) | 5.3 (16.2) | 0.5 (1.4) |
2020, wk 2–8 | 29.9 | 1.1 (3.8) | 2.4 (8.1) | 0.4 (1.4) | 6.0 (20.1) | 14.4 (48.3) | 5.4 (18.2) | 0.0 (0.0) |
2020, wk 9–11 | 27.3 | 0.3 (1.2) | 1.3 (4.9) | 0.3 (1.2) | 5.3 (19.5) | 14.0 (51.2)h | 6.0 (22.0) | 0.0 (0.0) |
2020, wk 12–13 | 17.5 | 0.0 (0.0) | 0.5 (2.9) | 1.5 (8.6) ↑ | 2.5 (14.3) | 6.0 (34.3) | 7.0 (40.0)i | 0.0 (0.0) |
2020, wk 14–17 | 15.5 | 0.3 (1.6) | 0.8 (4.8) | 1.0 (6.5) ↑ | 2.3 (14.5) | 9.3 (59.7) | 2.0 (12.9) | 0.0 (0.0) |
Stage IV | ||||||||
2018/2019, wk 2–17 | 17.2 | 1.6 (9.3) | 0.3 (2.0) | 0.0 (0.2) | 0.6 (3.5) | 5.7 (33.3) | 7.4 (43.3) | 1.5 (8.5) |
2020, wk 2–8 | 19.1 | 3.1 (16.4) ↑ | 0.4 (2.2) | 0.0 (0.0) | 0.9 (4.5) | 6.3 (32.8) | 7.4 (38.8) | 1.0 (5.2) |
2020, wk 9–11 | 16.3 | 2.0 (12.2) | 0.7 (4.1) | 0.0 (0.0) | 0.7 (4.1) | 5.3 (32.7)j | 7.7 (46.9) | 0.0 (0.0) |
2020, wk 12–13 | 12.0 | 1.0 (8.3) | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.0) | 3.5 (29.2)k | 7.5 (62.5) ↑ | 0.0 (0.0) |
2020, wk 14–17 | 13.5 | 1.5 (11.1) | 0.0 (0.0) | 0.0 (0.0) | 0.3 (1.9) | 5.8 (42.6)l | 5.3 (38.9)m | 0.8 (5.6) |